Clinical Trials Directory

Trials / Suspended

SuspendedNCT03337256

Direct Discharge of Patients With Upper Gastrointestinal Bleeding From the Emergency Department After Endoscopy

Direct Discharge of Patients With Upper Gastrointestinal Bleeding From the Emergency Department After Endoscopy: A Feasibility Study (GIB Score 002 Study)

Status
Suspended
Phase
N/A
Study type
Interventional
Enrollment
762 (estimated)
Sponsor
Chinese University of Hong Kong · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Acute upper gastrointestinal bleeding (UGIB) is a common cause for attendance to the Emergency Department with a wide range of clinical severity, ranging from insignificant to life-threatening. While there is robust data to support the benefit of upper endoscopy within 24 hours of admission, the implementation of early upper endoscopy while patients are still in the emergency room has not been widely accepted due to lack of added benefit in terms of patient outcome such as mortality and re-bleeding rate. However, the use of upper endoscopy in the emergency room with the purpose of facilitating early discharge of low risk patients with upper gastrointestinal bleeding has not been studied.

Detailed description

The Glasgow Blatchford Score (GBS) was developed in 2000 to identify very low risk patients who would not need any intervention and were of low risk of rebleeding and death. The GBS used objective clinical parameters that could be easily obtained in the emergency department and did not use any endoscopy findings as parameters. Unlike the Rockall score which was designed to identify high risk patients, the GBS was used to identify low risk patients who could be safely discharged from the emergency department without endoscopy and studies have shown it to be superior in this regard. The main limitation of GBS is its low specificity with only 4-8% of all patients presenting with upper gastrointestinal bleeding stratified as low risk. Furthermore, the GBS was derived from a Scottish gastrointestinal bleeding registry and may not be applicable to the local population. Suitable patients attending the Accident \& Emergency Department for symptoms of upper gastrointestinal bleeding will be identified and recruited by the Accident \& Emergency physicians. Patients presenting to Endoscopy Centre after admission will also be recruited to collect clinical data. Univariate analysis was carried out on the development set using Pearson's chi-square method to examine the association among the factors on the outcome. Variables significantly associated with 30 day re-attendance rate in univariate analyses (P\<=0.1) will be entered in multivariate logistic regression models. Risk factors which retained significance in multivariate analyses will be selected for incorporation into the risk score. A weighting will be assigned to each independent variable in the risk score, applying the corresponding adjusted odds ratio (AOR). The risk score for each subject is the sum of all the risk factors. To evaluate the predictive ability of the scoring system, a receiver operating characteristic (ROC) curve was constructed and the area under the curve (AUC) was delineated. A concordance (c)-statistics was used to reflect the discriminative ability of the prediction tool. Cost-effective economical model will be used in cost effective analysis of the use of early discharge strategy.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTGI bleeding scoreRisk factor Score component value Age (years) 15-29 -2 30-44 -1.5 45-59 0 60-74 1.5 * 75 2.5 Haemoglobin(g/L) * 10.0 0 \<9.9 2 Systolic blood pressure (mmHg) * 110 0 90-109 1.5 \<90 2.5 Pulse (beats per min) \<100 0 * 100 1.5 Creatinine (mmol/L) \<200 0 * 200 3.5 Number of blood transfusion 0 0 1 1.5 * 2 2 Presenting symptom Melaena -1.5 Drug treatment Acid blcoking drug 1.5 anticoagulant 3 Endoscopy findings Clean-based ulcer -2 SRH or blood in stomach 4 Varices 5

Timeline

Start date
2015-09-01
Primary completion
2025-08-31
Completion
2026-02-28
First posted
2017-11-08
Last updated
2020-04-09

Locations

2 sites across 1 country: Hong Kong

Source: ClinicalTrials.gov record NCT03337256. Inclusion in this directory is not an endorsement.